132 related articles for article (PubMed ID: 7280120)
21. A role for prostaglandins and thromboxanes in the exposure of platelet fibrinogen receptors.
Bennett JS; Vilaire G; Burch JW
J Clin Invest; 1981 Oct; 68(4):981-7. PubMed ID: 6270196
[TBL] [Abstract][Full Text] [Related]
22. The response of platelets to epinephrine in storage pool deficiency--evidence pertaining to the role of adenosine diphosphate in mediating primary and secondary aggregation.
Weiss HJ; Lages B
Blood; 1988 Nov; 72(5):1717-25. PubMed ID: 2846091
[TBL] [Abstract][Full Text] [Related]
23. Zinc-induced platelet aggregation is mediated by the fibrinogen receptor and is not accompanied by release or by thromboxane synthesis.
Heyns Adu P; Eldor A; Yarom R; Marx G
Blood; 1985 Jul; 66(1):213-9. PubMed ID: 2988668
[TBL] [Abstract][Full Text] [Related]
24. Platelet storage pool deficiency and prostaglandin synthesis in chronic granulocytic leukaemia.
Gerrard JM; Stoddard SF; Shapiro RS; Coccia PF; Ramsay NK; Nesbit ME; Rao GH; Krivit W; White JG
Br J Haematol; 1978 Dec; 40(4):597-607. PubMed ID: 281970
[TBL] [Abstract][Full Text] [Related]
25. Prostaglandin E2 potentiation of platelet aggregation induced by LASS endoperoxide: absent in storage pool disease, normal after aspirin ingestion.
Weiss HJ; Willis AL; Kuhn D; Brand H
Br J Haematol; 1976 Feb; 32(2):257-72. PubMed ID: 1247498
[TBL] [Abstract][Full Text] [Related]
26. Pathways responsible for platelet hypersensitivity in rats with diabetes. I. Streptozocin-induced diabetes.
Winocour PD; Kinlough-Rathbone RL; Mustard JF
J Lab Clin Med; 1986 Feb; 107(2):148-53. PubMed ID: 3080538
[TBL] [Abstract][Full Text] [Related]
27. Released adenosine diphosphate stabilizes thrombin-induced human platelet aggregates.
Cattaneo M; Canciani MT; Lecchi A; Kinlough-Rathbone RL; Packham MA; Mannucci PM; Mustard JF
Blood; 1990 Mar; 75(5):1081-6. PubMed ID: 2137716
[TBL] [Abstract][Full Text] [Related]
28. Proceedings: Study of albinism in relation to Hermanský-Pudlák syndrome.
Hermanský F; Cieslar P; Matousová O; Smetana K
Thromb Diath Haemorrh; 1975 Sep; 34(1):360. PubMed ID: 1188819
[No Abstract] [Full Text] [Related]
29. Biochemical studies in Hermansky-Pudlak syndrome.
Gerritsen SM; Akkerman JW; Staal G; Roelofsen B; Koster JF; Sixma JJ
Scand J Haematol; 1979 Aug; 23(2):161-8. PubMed ID: 493877
[TBL] [Abstract][Full Text] [Related]
30. Malondialdehyde formation as an indicator of prostaglandin production by human platelets.
Smith JB; Ingerman CM; Silver MJ
J Lab Clin Med; 1976 Jul; 88(1):167-72. PubMed ID: 932533
[TBL] [Abstract][Full Text] [Related]
31. Analysis of platelet cytoskeleton assembly during platelet activation in Hermansky-Pudlak syndrome and thrombasthenia.
Fujimura K; Fujimoto T; Takemoto M; Oda K; Shimomura T; Maehama S; Kuramoto A
Thromb Haemost; 1990 Feb; 63(1):103-11. PubMed ID: 2339346
[TBL] [Abstract][Full Text] [Related]
32. Investigation on a selective non-prostanoic thromboxane antagonist, BM 13.177, in human platelets.
Patscheke H; Stegmeier K
Thromb Res; 1984 Feb; 33(3):277-88. PubMed ID: 6424261
[TBL] [Abstract][Full Text] [Related]
33. Studies of platelets in a variant of the Hermansky-Pudlak syndrome.
White JG; Edson JR; Desnick SJ; Witkop CJ
Am J Pathol; 1971 May; 63(2):319-32. PubMed ID: 5090642
[No Abstract] [Full Text] [Related]
34. Benzodiazepines inhibit human platelet activation: comparison of the mechanism of antiplatelet actions of flurazepam and diazepam.
Romstedt K; Huzoor-Akbar
Thromb Res; 1985 May; 38(4):361-74. PubMed ID: 2990062
[TBL] [Abstract][Full Text] [Related]
35. In vitro and in vivo functions of thrombin-treated platelets.
Reimers HJ; Kinlough-Rathbone RL; Cazenave JP; Senyi AF; Hirsh J; Packham MA; Mustard JF
Thromb Haemost; 1976 Feb; 35(1):151-66. PubMed ID: 785686
[TBL] [Abstract][Full Text] [Related]
36. Effects of N-acetylglucosamine and platelet inhibitors on the synergistic interaction of platelets and aggregating agents in the presence of wheat germ agglutinin.
Tandon NN; Ordinas A; Jamieson GA
Biochim Biophys Acta; 1982 Nov; 719(2):388-95. PubMed ID: 6817815
[TBL] [Abstract][Full Text] [Related]
37. Labile aggregation stimulating substance (LASS): the factor from storage pool deficient platelets correcting defective aggregation and release of aspirin treated normal platelets.
Gerrard JM; White JG; Rao GH; Krivit W; Witkop CJ
Br J Haematol; 1975 Apr; 29(4):657-65. PubMed ID: 1191568
[TBL] [Abstract][Full Text] [Related]
38. Irreversible platelet aggregation does not depend on lipoxygenase metabolites.
Rao GH; Radha E; White JG
Biochem Biophys Res Commun; 1985 Aug; 131(1):50-7. PubMed ID: 3929780
[TBL] [Abstract][Full Text] [Related]
39. Biphasic aggregation responses to ADP and epinephrine in some storage pool deficient platelets: relationship to the role of endogenous ADP in platelet aggregation and secretion.
Lages B; Weiss HJ
Thromb Haemost; 1980 Jun; 43(2):147-53. PubMed ID: 7455974
[TBL] [Abstract][Full Text] [Related]
40. Phenylbutazone inhibition of equine platelet function.
Meyers KM; Lindner C; Katz J; Grant B
Am J Vet Res; 1979 Feb; 40(2):265-70. PubMed ID: 464364
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
